Abstract:Background: Polycythemia vera (PV) is a myeloproliferative neoplasm. Ropeginterferon alfa-2b is a new -generation polyethylene glycol -conjugated proline-interferon. It is approved for the treatment of PV at a starting dose of 100 mu g (50 mu g for patients receiving hydroxyurea (HU)) and dose titrations up to 500 mu g by 50 mu g increments. The study was aimed at assessing its efficacy and safety at a higher starting dose and simpler intra-patient dose escalation. Methods: Forty-nine patients with PV having HU intolerance from major hospitals in China were treated biweekly with an initial dose of 250 mu g, followed by 350 mu g and 500 mu g thereafter if tolerated. Complete hematological response (CHR) was assessed every 12 weeks based on the European LeukemiaNet criteria. The primary endpoint was the CHR rate at week 24. The secondary endpoints included CHR rates at weeks 12, 36 and 52, changes of JAK2 V617F allelic burden, time to first CHR, and safety assessments. Results: The CHR rates were 61.2%, 69.4% and 71.4% at weeks 24, 36, and 52, respectively. Mean allele burden of the driver mutation JAK2 V617F declined from 58.5% at baseline to 30.1% at 52 weeks. Both CHR and JAK2 V617F allele burden reduction showed consistent increases over the 52 weeks of the treatment. Twentynine patients (63.0%) achieved partial molecular response (PMR) and two achieved complete molecular response (CMR). The time to CHR was rapid and median time was 5.6 months according to central lab results. The CHRs were durable and median CHR duration time was not reached at week 52. Mean spleen index reduced from 55.6 cm 2 at baseline to 50.2 cm 2 at week 52. Adverse events (AEs) were mostly mild or moderate. Most common AEs were reversible alanine aminotransferase and aspartate aminotransferase increases, which were not associated with significant elevations in bilirubin levels or jaundice. There were no grade 4 or 5 AEs. Grade 3 AEs were reversible and manageable. Only one AE led to discontinuation. No incidence of thromboembolic events was observed. Conclusion: The 250-350-500 mu g dosing regimen was well tolerated and effectively induced CHR and MR and managed spleen size increase. Our findings demonstrate that ropeginterferon alfa-2b at this dosing regimen can provide an effective management of PV and support using this dosing regimen as a treatment option.

The evolving landscape of polycythemia vera therapies

Polycythemia vera: past, present and future

Moving toward disease modification in polycythemia vera

Effective Management of Polycythemia Vera with Ropeginterferon Alfa-2b Treatment

A Phase II Trial to Assess the Efficacy and Safety of Ropeginterferon Α-2B in Chinese Patients with Polycythemia Vera.

How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction

Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera

[Treatment strategies for low-risk polycythemia vera]

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?

A New Dosing Regimen of Ropeginterferon Alfa-2B is Highly Effective and Tolerable: Findings from a Phase 2 Study in Chinese Patients with Polycythemia Vera

Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety

Interferons in the treatment of myeloproliferative neoplasms

Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes

Rise of the planet of rare anemias: An update on emerging treatment strategies

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine

Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes

Developmental Therapeutics in Myeloproliferative Neoplasms

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?